The Global Polio Eradication Initiative (GPEI) recently launched a Make Polio History campaign to rally supporters of polio eradication. This effort included the novel oral polio type 2 (nOPV2) vaccine, which was launched in response to poliovirus type 2 outbreaks,
Over the past three years, approximately 1 billion nOPV2 doses have been administered in more than 35 countries worldwide, says the GPEI.

As the world looks forward to a healthy 2024, various health agencies recently reported signs of changing influenza and respiratory syncytial virus (RSV) detections.
From a global perspective, the World Health Organization (WHO) Influenza Update N° 462 confirmed the influenza season increased in the temperate Northern Hemisphere,

January 2024 marks the 30th anniversary of the Oral Rabies Vaccination Program (ORVP) in South Texas, which has successfully controlled and prevented domestic dog / coyote variant rabies and gray fox variant rabies infections among wildlife, livestock, and people.
No human rabies cases have been attributable to any of these variants in Texas since the ORVP began.
Texas Department of State Health Services’ airdrop flights launched on January 9, 2024, from Edinburg in Hidalgo County, distributing rabies vaccine baits over 18 border counties.

With the decreasing uptake of well-known influenza and COVID-19 vaccines, leaders of the U.S. Food and Drug Administration (FDA) recently published an insightful editorial regarding the future of virology in the United States.
Published by The JAMA Network on January 5, 2024, Peter Marks, MD, PhD, and Robert Califf, MD wrote a Viewpoint titled: Is Vaccination Approaching a Dangerous Tipping Point?

The Centers for Disease Control and Prevention (CDC) today announced a change in its guidance regarding using Nirsevimab (Beyfortus™) in a Clinician Outreach and Communication Activity email.
As of January 5, 2023, the CDC says that infants and children recommended to receive Beyfortus should be immunized as quickly as possible.

Throughout 2023, the Pan American Health Organization (PAHO) reported significant increases in the number of dengue virus cases. By mid-December, the Region had experienced about 57% increase in dengue cases compared with data published in 2022.
And the Region experienced a case fatality rate of 0.049%.
The ongoing dengue outbreak has significantly impacted the Federative Republic of Brazil, which confirmed over 1.6 million dengue cases in 2023.

The 37th meeting of the World Health Organization (WHO) Emergency Committee under the International Health Regulations on the international spread of poliovirus was convened on December 12, 2023.
The WHO's Committee unanimously agreed that the risk of the international spread of poliovirus remains a Public Health Emergency of International Concern and recommended its extension and Temporary Recommendations for a further three months.
In 2022, the United States was added to this list of countries where polio was identified.  

An Original Article published today reported a second-generation monoclonal antibody (mAb) reduced hospitalizations among infants with respiratory syncytial virus (RSV)-associated lower respiratory tract infection.
The recently approved single-dose Beyfortus™ (nirsevimab) was found in a phase 3 clinical study that (0.3%) of infants who received Beyfortus were hospitalized for RSV-associated lower respiratory tract infection compared with 1.5% of those who received standard care.

The global outbreak of dengue has significantly increased over the past two decades. From 2000 to 2019, the World Health Organization (WHO) documented a ten-fold surge in dengue cases.
According to the WHO Disease Outbreak News (DON498) published on December 21, 2023, this year's dengue upsurge has been characterized by a significant increase in the scale and simultaneous occurrence.
Moreover, the mosquito-transmitted disease impacts regions previously unaffected by dengue as the range of Aedes aegypti and Aedes albopictus mosquitoes increases.

While travel vaccination services are generally offered on land by clinics and pharmacies in the United States, the Centers for Disease Control and Prevention (CDC) recently suggested these types of services could go-to-sea.
On December 18, 2023, the CDC published updated guidance for cruise ships managing Acute Respiratory Illnesses (ARI). 
This CDC document guides cruise ships originating from or stopping in the U.S. to help prevent, diagnose, and medically manage ARI caused by the SARS-CoV-2 betacorinavirus, influenza, or Respiratory syncytial virus (RSV).